This article is an independent overview of advancements in the treatment of alopecia areata, based on recent clinical studies. It is intended to provide healthcare professionals with up-to-date, evidence-based information.
Introduction
Alopecia areata (AA) is a chronic, immune-mediated condition leading to non-scarring alopecia on the scalp and other hair-bearing areas.1 Affecting up to 2% of the global population, it is the second most common cause of hair loss after androgenetic alopecia.1,2 AA can manifest at any age, though prevalence appears higher in children (1.92%) compared to adults (1.47%), with a higher incidence in females, particularly those experiencing late-onset AA (age >50 years).1 Notably, 40% of patients will have their first occurrence of AA by the age of 20, and between 83–88% will experience it by the age of 40.2 Clinically, AA presents in various patterns: the most common being patchy alopecia, but also in patterns such as ophiasis (band-like hair loss in the parieto-temporo-occipital area), sisaipho (hair loss in the fronto-parieto-temporal area), diffuse alopecia, alopecia totalis (complete scalp hair loss), and alopecia universalis (complete scalp and body hair loss).1
The disease’s unpredictable nature and absence of curative therapies result in a significant psychosocial burden for patients and their families, making AA a condition that requires careful management and attention.2
Login to read more
